Novo Nordisk puts AI at the centre of its clinical strategy - Pharmaceutical Technology

Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation. Novo Nordisk’s Ibrahim Kamstrup-Akkaoui outlines how the Danish GLP-1 giant is embedding AI into its clinical foundation. Novo Nordisk aims to rapidly process data, set up systems that can simulate trials virtually, and predict regulators’ responses to approval bids by leveraging AI. Credit: oleschwander/Shutterstock.com In the last few years, pharma leaders have been scrambling to see how artificial intelligence (AI) can augment every aspect of their business to increase output, accelerate timelines, and slash costs. Clinical research and development (R&D) is at the…

Source: Pharmaceutical Technology